{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:17:00Z","timestamp":1792081020094,"version":"4.4.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-024-03284-3","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T19:01:59Z","timestamp":1728414119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Risk factors for relapse of immune-related pneumonitis after 6-week oral prednisolone therapy: a follow-up analysis of a phase II study"],"prefix":"10.1186","volume":"24","author":[{"given":"Masato","family":"Karayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Inui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironao","family":"Hozumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Furuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Asada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikio","family":"Toyoshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Inami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Funayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Goshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"3284_CR1","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974\u201382.","journal-title":"J Clin Oncol"},{"key":"3284_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378:158\u201368.","journal-title":"N Engl J Med"},{"key":"3284_CR3","doi-asserted-by":"publisher","unstructured":"Chen TW, Razak AR, Bedard PL, Siu LL, Hansen AR. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol [Internet]. Elsevier Masson SAS; 2015;26:1824\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdv182","DOI":"10.1093\/annonc\/mdv182"},{"key":"3284_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2022-004670","volume":"10","author":"BC Tiu","year":"2022","unstructured":"Tiu BC, Zubiri L, Iheke J, Pahalyants V, Theodosakis N, Ugwu-Dike P, et al. Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study. J Immunother Cancer. 2022;10:1\u201312.","journal-title":"J Immunother Cancer"},{"key":"3284_CR5","doi-asserted-by":"crossref","unstructured":"Koyauchi T, Inui N, Karayama M, Kitahara Y, Takuma S, Amano Y, Clinical Outcomes of Anti-programmed Death-1 Antibody\u2013Related Pneumonitis in Patients with Non-Small Cell Lung Cancer. SN Compr Clin Med. Springer Science and Business, Media LLC et al. 2020;2:570\u20138.","DOI":"10.1007\/s42399-020-00259-3"},{"key":"3284_CR6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","volume":"35","author":"J Naidoo","year":"2017","unstructured":"Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, et al. Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy. J Clin Oncol. 2017;35:709\u201317.","journal-title":"J Clin Oncol"},{"key":"3284_CR7","doi-asserted-by":"publisher","unstructured":"Atchley WT, Alvarez C, Saxena-Beem S, Schwartz TA, Ishizawar RC, Patel KP et al. Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer: Real-World Incidence, Risk Factors, and Management Practices Across Six Health Care Centers in North Carolina. Chest [Internet]. Elsevier Inc; 2021;160:731\u201342. https:\/\/doi.org\/10.1016\/j.chest.2021.02.032","DOI":"10.1016\/j.chest.2021.02.032"},{"key":"3284_CR8","doi-asserted-by":"publisher","unstructured":"Suresh K, Voong KR, Shankar B, Forde PM, Ettinger DS, Marrone KA et al. Pneumonitis in Non\u2013Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors. J Thorac Oncol [Internet]. Elsevier Inc; 2018;13:1930\u20139. https:\/\/doi.org\/10.1016\/j.jtho.2018.08.2035","DOI":"10.1016\/j.jtho.2018.08.2035"},{"key":"3284_CR9","doi-asserted-by":"publisher","first-page":"20200409","DOI":"10.1259\/bjr.20200409","volume":"93","author":"TW Nobashi","year":"2020","unstructured":"Nobashi TW, Nishimoto Y, Kawata Y, Yutani H, Nakamura M, Tsuji Y, et al. Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers. Br J Radiol. 2020;93:20200409.","journal-title":"Br J Radiol"},{"key":"3284_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/1759-7714.13736","volume":"12","author":"T Isono","year":"2021","unstructured":"Isono T, Kagiyama N, Takano K, Hosoda C, Nishida T, Kawate E, et al. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors. Thorac Cancer. 2021;12:153\u201364.","journal-title":"Thorac Cancer"},{"key":"3284_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.21037\/tlcr-22-72","volume":"11","author":"Y Chao","year":"2022","unstructured":"Chao Y, Zhou J, Hsu S, Ding N, Li J, Zhang Y, et al. Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer. Transl Lung Cancer Res. 2022;11:295\u2013306.","journal-title":"Transl Lung Cancer Res"},{"key":"3284_CR12","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1200\/JCO.19.00318","volume":"37","author":"V Ellen Maher","year":"2019","unstructured":"Ellen Maher V, Fernandes LL, Weinstock C, Tang S, Agarwal S, Brave M, et al. Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody. J Clin Oncol. 2019;37:2730\u20137.","journal-title":"J Clin Oncol"},{"key":"3284_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejca.2021.03.016","volume":"150","author":"D Fujimoto","year":"2021","unstructured":"Fujimoto D, Miura S, Yoshimura K, Wakuda K, Oya Y, Yokoyama T, et al. Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-na\u00efve patients with non-squamous non-small cell lung cancer: a multicentre, retrospective cohort study. Eur J Cancer Elsevier Ltd. 2021;150:63\u201372.","journal-title":"Eur J Cancer Elsevier Ltd"},{"key":"3284_CR14","doi-asserted-by":"publisher","first-page":"381","DOI":"10.21037\/tlcr-22-168","volume":"11","author":"H Tao","year":"2022","unstructured":"Tao H, Li F, Wu D, Ji S, Liu Q, Wang L, et al. Rate and risk factors of recurrent immune checkpoint inhibitor-related pneumonitis in patients with lung cancer. Transl Lung Cancer Res. 2022;11:381\u201392.","journal-title":"Transl Lung Cancer Res"},{"key":"3284_CR15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/CJI.0000000000000451","volume":"46","author":"P Tan","year":"2023","unstructured":"Tan P, Huang W, He X, Lv F, Cui Y, Du S. Risk factors for Refractory Immune checkpoint inhibitor-related pneumonitis in patients with Lung Cancer. J Immunother. 2023;46:64\u201373.","journal-title":"J Immunother"},{"key":"3284_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2023-007056","volume":"11","author":"M Karayama","year":"2023","unstructured":"Karayama M, Inui N, Inoue Y, Yasui H, Hozumi H, Suzuki Y, et al. Six-week oral prednisolone therapy for immune-related pneumonitis: a single-arm phase II study. J Immunother Cancer. 2023;11:1\u20137.","journal-title":"J Immunother Cancer"},{"key":"3284_CR17","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of Immune-related adverse events in patients treated with Immune checkpoint inhibitor therapy: ASCO Guideline Update. J Clin Oncol. 2021;39:4073\u2013126.","journal-title":"J Clin Oncol"},{"key":"3284_CR18","doi-asserted-by":"publisher","unstructured":"Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up \u2606. Ann Oncol [Internet]. European Society for Medical Oncology; 2022;33:1217\u201338. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.001","DOI":"10.1016\/j.annonc.2022.10.001"},{"key":"3284_CR19","unstructured":"Common Terminology Criteria for Adverse Events. (CTCAE) v5.0 [Internet]. Natinal Cancer Inst. 2017 [cited 2019 Mar 15]. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50"},{"key":"3284_CR20","doi-asserted-by":"publisher","unstructured":"Johkoh T, Lee KS, Nishino M, Travis WD, Ryu JH, Lee HY et al. Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society. Chest [Internet]. The Authors; 2021;159:1107\u201325. https:\/\/doi.org\/10.1016\/j.chest.2020.11.027","DOI":"10.1016\/j.chest.2020.11.027"},{"key":"3284_CR21","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJMra2116777","volume":"386","author":"TE King","year":"2022","unstructured":"King TE, Lee JS. Cryptogenic organizing pneumonia. New Engl J Med. 2022;386:1058\u201369.","journal-title":"New Engl J Med"},{"key":"3284_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-023-10649-0","volume":"23","author":"L Pang","year":"2023","unstructured":"Pang L, Xie M, Ma X, Huang A, Song J, Yao J, et al. Clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. BMC Cancer. 2023;23:1\u20139.","journal-title":"BMC Cancer"},{"key":"3284_CR23","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1183\/09031936.06.00013505","volume":"28","author":"JF Cordier","year":"2006","unstructured":"Cordier JF. Cryptogenic organising pneumonia. Eur Respir J. 2006;28:422\u201346.","journal-title":"Eur Respir J"},{"key":"3284_CR24","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1365-2125.2008.03177.x","volume":"66","author":"DK Ernawati","year":"2008","unstructured":"Ernawati DK, Stafford L, Hughes JD. Amiodarone-induced pulmonary toxicity. Br J Clin Pharmacol. 2008;66:82\u20137.","journal-title":"Br J Clin Pharmacol"},{"key":"3284_CR25","doi-asserted-by":"crossref","unstructured":"Prediction of BCNU Pulmonary Toxicity in Patients with Malignant Gliomas \u2014 An Assessment of Risk Factors, Patricia A, Aronin MS, Mahaley. Jr, Seth A Rudn Lynn Dudka, RN, James F Donohue, Robert G Selker Earl Moore,. 1980;303:183\u20138.","DOI":"10.1056\/NEJM198007243030403"},{"key":"3284_CR26","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1001\/jama.1978.03280460080024","volume":"239","author":"WG Brown","year":"1978","unstructured":"Brown WG, Hasan FM, Barbee RA. Reversibility of severe bleomycin-lnduced Pneumonitis. JAMA J Am Med Assoc. 1978;239:2012\u20134.","journal-title":"JAMA J Am Med Assoc"},{"key":"3284_CR27","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","volume":"6","author":"C Dolladille","year":"2020","unstructured":"Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, et al. Immune checkpoint inhibitor rechallenge after Immune-related adverse events in patients with Cancer. JAMA Oncol. 2020;6:865\u201371.","journal-title":"JAMA Oncol"},{"key":"3284_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2174\/1874306401206010063","volume":"6","author":"M Schwaiblmair","year":"2012","unstructured":"Schwaiblmair M, Behr W, Haeckel T, M\u00e4rkl B, Foerg W. Berghaus1 T. Drug-induced interstitial lung diseases. Open Respir Med J. 2012;6:63\u201374.","journal-title":"Open Respir Med J"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03284-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-024-03284-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03284-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T07:02:30Z","timestamp":1728457350000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-024-03284-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3284"],"URL":"https:\/\/doi.org\/10.1186\/s12890-024-03284-3","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"16 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Review Board of Hamamatsu University School of Medicine (No. 19\u2013037).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Each patient provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"495"}}